Large companies, particularly global pharmaceutical businesses, are increasingly willing to initiate antitrust litigation, according to Brian Savage, vice president and general counsel of generic drug giant Teva Pharmaceuticals.

Speaking at Dechert’s annual antitrust event, revived Tuesday in Philadelphia after a three-year pandemic-induced hiatus, Savage highlighted a number of issues occupying the lawyers at major enterprises like Teva given a growing globalized network of antitrust and intellectual property regulation and litigation.